Topiramate: Difference between revisions
From SEHK Wiki
| Line 90: | Line 90: | ||
|- | |- | ||
|'''Rare''' (<0.1% of incidence)' | |'''Rare''' (<0.1% of incidence)' | ||
|*Hepatic failure, hepatitis | | | ||
*Hepatic failure, hepatitis | |||
*Periorbital oedema | *Periorbital oedema | ||
*Raynaud’s syndrome | *Raynaud’s syndrome | ||
Revision as of 22:49, 5 October 2020
Introduction
Topiramate is a medication used to treat epilepsy and prevent migraines. For epilepsy this includes treatment for generalized or focal seizures. It is also used as adjunctive treatment for seizures associated with Lennox-Gastaut syndrome.
| Generic Name 藥名 | HA Code 藥物代碼 | Classification藥物分類 |
|---|---|---|
| Topiramate Tablet 25 mg | TOPI01 | P1S1S3 |
| Topiramate Tablet 50 mg | TOPI01 | P1S1S3 |
| Topiramate Tablet 100 mg | TOPI03 | P1S1S3 |
Mechanism of Action
Anticonvulsant medication. It inhibits the sodium channels, calcium channels, GABA-A receptors, and carbonic anhydrase isoenzymes, contributing to the antiseizure effects.
Dosage
| For both adjunctive and monotherapy of epilepsy | By mouth
ADULT:
|
|---|---|
For monotherapy, CHILD 6 – 17 years:
| |
As adjunctive therapy, CHILD form 2 years of age:
| |
| Migraine prophylaxis | By mouth
ADULT:
|
As with other antiepileptics, withdrawal of topiramate therapy should be made gradually to avoid precipitating an increase in the frequency of seizures. The daily dose should be decreased by 50 to 100 mg at weekly intervals.
Side Effects
Adverse drug reactions associated with the use of topiramate include:
| Very Common ((>10% incidence) |
|
| Common (1-10% incidence) |
|
| Rare (<0.1% of incidence)' |
|
